The European Commission's recent authorization of Regeneron's bispecific antibody drug Ordspono (odronextamab) for the treatment of two types of lymphoma marks a significant milestone in the European market. Garnering approval for use across 27 European Union countries, Ordspono is now
The early-stage biotech investment landscape has undergone substantial changes in recent years. From the buoyant investment period during the pandemic to the current stabilization at pre-pandemic levels, the sector faces a mix of challenges and evolving strategies. One of the most significant
The Korea Biopharma Excellence Awards (KBEA) 2024 marked a significant moment for Avantor, a leader in providing mission-critical products and services across life sciences and advanced technologies. Avantor’s recognition at these awards underscores their unwavering commitment to innovation and e
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is such an innovative medicine, that it seems like something straight out of a science fiction novel. This gene editing technology allows scientists to precisely target spots in our DNA to fix mutations or stop disease-ridden parts
Sutro Biopharma has announced a significant step forward in the fight against lung cancer by initiating a global Phase 2 clinical trial, aptly named REFRαME-L1, for their innovative drug luveltamab tazevibulin (luvelta). This trial aims to evaluate the safety and efficacy of luvelta in adults with
Eli Lilly's groundbreaking medication, tirzepatide, also known as Mounjaro and Zepbound, has demonstrated remarkable success in reducing the risk of Type 2 diabetes and promoting weight loss. The results from the extensive Phase 3 trial, named SURMOUNT-1, have sparked significant interest and
In an impressive turn of events, the U.S. Food and Drug Administration (FDA) has lifted the partial hold on BioNTech and MediLink Therapeutics' clinical trial for their groundbreaking Antibody-Drug Conjugate (ADC) candidate BNT326/YL202. Originally put on hold due to serious safety concerns,
VGXI Inc., a prominent Contract Development and Manufacturing Organization (CDMO) specializing in nucleic acid biopharmaceuticals, is making significant strides in the biopharmaceutical industry. Their recent inclusion in the Biopharmaceutical Manufacturing Preparedness (BioMAP) Consortium
The biopharmaceutical industry, or biopharma, stands at the forefront of medicine and biotechnology, bringing revolutionary advancements to patient care and medical treatments. Biopharma focuses on developing drugs from biological sources, offering a wide range of therapies that are changing lives.
Maccabi Health Services has taken a significant step toward safeguarding its medical and Internet of Things (IoT) devices from ransomware attacks by partnering with Cynerio, a startup specializing in healthcare cybersecurity. Being the second-largest health maintenance organization in Israel, which
